SHANG.FOS.PHARM.GR.H YC 1 (08HH) — Cash Flow-to-Debt Ratio
SHANG.FOS.PHARM.GR.H YC 1 (08HH) has a Cash Flow-to-Debt Ratio of 0.09x as of December 2025, meaning its operating cash flow of €5.21 Billion could theoretically repay 0% of its total liabilities (€58.21 Billion) in one year. See SHANG.FOS.PHARM.GR.H YC 1 (08HH) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SHANG.FOS.PHARM.GR.H YC 1 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for SHANG.FOS.PHARM.GR.H YC 1 across 5 annual periods. Also explore SHANG.FOS.PHARM.GR.H YC 1 equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
Year-by-year debt coverage analysis for SHANG.FOS.PHARM.GR.H YC 1. For market capitalisation and broader financial context, see market value of SHANG.FOS.PHARM.GR.H YC 1.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | €5.21 Billion | €58.21 Billion | ▲ +15.1% |
| 2024 | 0.08x | €4.48 Billion | €57.53 Billion | ▲ +29.6% |
| 2023 | 0.06x | €3.41 Billion | €56.85 Billion | ▼ -24.5% |
| 2022 | 0.08x | €4.22 Billion | €53.05 Billion | ▼ -9.3% |
| 2021 | 0.09x | €3.94 Billion | €44.93 Billion | — |